Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany

This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. The use of amifostine, with the intention of reducing haematological and oral toxicities associated with radiochemotherapy treatments in patients with cancer, proved to be effective and resulted in cost-savings from the perspective of the third-party payer.